Otilimab

奥替利单抗

Report date: 2022/06/02 15:53:34

Base Information

Drug NameOtilimab
Drug Alias NameGSK-3196165MOR-04357MOR-103GSK-165
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionMacrophage colony stimulating factor 2 inhibitors
TargetsMacrophage colony stimulating factor 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Multiple SclerosisOsteoarthritis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesUniversity Of Melbourne
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Trading Services LtdGlaxosmithkline PlcRenmin Hospital Of Wuhan University +[4] 
Inactive CompaniesMorphosys AgGlaxo Operations Uk Ltd
Active IndicationsCoronavirus Disease 2019 (COVID-19)Arthritis, RheumatoidSpondylarthritis +[5] 
Inactive IndicationsMultiple SclerosisOsteoarthritis

Other Information

ATC CodeN/A
Related LinksN/A